BACE1 CRISPR/high-fidelity Cas13Y gene therapy (HuidaGene Therapeutics)

N/A

Report date: 2025/08/11 17:53:12

Base Information

Drug NameBACE1 CRISPR/high-fidelity Cas13Y gene therapy (HuidaGene Therapeutics)
Drug Alias NamehfCas13Y-BACE1-gRNA
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vectorCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas13
Mechanisms of ActionBeta-secretase 1 inhibitorsNeuroprotectants
TargetsBeta-secretase 1
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHuidaGene Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHuidaGene Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A